Over the past two years, Kelly Partners (ASX:KPG) a direct competitor to Countplus has increased its share price from 0.89 to 4.70, an increase in value to shareholders of circa 520%. Countplus under Rowe’s leadership 1.10 to 0.90. A decrease in value. He has had 5 years and all we have seen is a negative return with pitiful dividends. The board needs to call Rowe to account and ask why. If Kelly can provide yield and growth, what is Rowe doing. There is not enough action, Accurium was blah blah, given there is an ongoing decline in self managed super funds and what is going on with new acquisitions? Where is the growth coming from? Let’s not be suckered by the upcoming half year reporting commentary from Rowe and the Chairman. The share price has been in the low 90s for almost two and a half years. What is going to change? When? The business’ performance is not good enough and change at the top is needed.
- Forums
- ASX - By Stock
- CUP
- Time to move the CEO on?
CUP
count limited
Add to My Watchlist
0.00%
!
$1.00

Time to move the CEO on?
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.00 |
Change
0.000(0.00%) |
Mkt cap ! $169.3M |
Open | High | Low | Value | Volume |
99.5¢ | $1.00 | 99.5¢ | $52.31K | 52.39K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 6330 | 99.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.00 | 69927 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 6330 | 0.995 |
2 | 5368 | 0.990 |
1 | 1708 | 0.980 |
1 | 17500 | 0.945 |
1 | 1064 | 0.940 |
Price($) | Vol. | No. |
---|---|---|
1.000 | 69927 | 3 |
1.010 | 10000 | 1 |
1.015 | 899 | 2 |
1.020 | 3302 | 2 |
1.030 | 49655 | 1 |
Last trade - 16.10pm 04/07/2025 (20 minute delay) ? |
Featured News
CUP (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online